Antimycotic Azoles (all routes except local only) updated on 01-29-2025

Ventricular septal defect

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17739
R74997		 Zhu - Fluconazole, 2020 Ventricular septal defect 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes Fluconazole not specified or mixed dose 1.02 [0.88;1.19] 175/37,648   8,525/1,872,961 8,700 37,648
ref
S17734
R74905		 Howley - Fluconazole, 2016 Perimembranous ventricular septal defect (VSD) 1st trimester case control unexposed (general population or NOS) Adjustment: No Fluconazole not specified or mixed dose 2.68 [0.54;13.30] C 2/8   1,443/13,049 1,445 8
ref
S17735
R74929		 Molgaard-Nielsen - Fluconazole, 2013 Ventricular septal defects 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Fluconazole not specified or mixed dose 1.24 [0.87;1.77] 31/7,352   3,172/968,236 3,203 7,352
ref
Total 3 studies 1.08 [0.90;1.29] 13,348 45,008
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Zhu - Fluconazole, 2020Zhu - Fluconazole, 2020 1.02[0.88; 1.19]8,70037,64876%ROB confusion: lowROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Howley - Fluconazole, 2016Howley - Fluconazole, 2016 2.68[0.54; 13.30]1,44581%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Molgaard-Nielsen - Fluconazole, 2013Molgaard-Nielsen - Fluconazole, 2013 1.24[0.87; 1.77]3,2037,35222%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 13% 1.08[0.90; 1.29]13,34845,0080.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.05[0.91; 1.21]11,90345,0000%NAZhu - Fluconazole, 2020 Molgaard-Nielsen - Fluconazole, 2013 2 case control studiescase control studies 2.68[0.54; 13.30]1,4458 -NAHowley - Fluconazole, 2016 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.08[0.90; 1.29]13,34845,00813%NAZhu - Fluconazole, 2020 Howley - Fluconazole, 2016 Molgaard-Nielsen - Fluconazole, 2013 3 Tags Adjustment   - No  - No 2.68[0.54; 13.30]1,4458 -NAHowley - Fluconazole, 2016 1   - Yes  - Yes 1.05[0.91; 1.21]11,90345,0000%NAZhu - Fluconazole, 2020 Molgaard-Nielsen - Fluconazole, 2013 2 Fluconazole not specified or mixed doseFluconazole not specified or mixed dose 1.08[0.90; 1.29]13,34845,00813%NAZhu - Fluconazole, 2020 Howley - Fluconazole, 2016 Molgaard-Nielsen - Fluconazole, 2013 3 All studiesAll studies 1.08[0.90; 1.29]13,34845,00813%NAZhu - Fluconazole, 2020 Howley - Fluconazole, 2016 Molgaard-Nielsen - Fluconazole, 2013 30.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.08[0.90; 1.29]13,34845,00813%NAZhu - Fluconazole, 2020 Howley - Fluconazole, 2016 Molgaard-Nielsen - Fluconazole, 2013 30.510.01.0